Smarter clinical trial supply planning

12 Dec 2019

New CTSuccess service helps to reduce the risk of delays and budget overspend.

Catalent has launched its new CTSucces clinical trial planning service, designed to support trial sponsors with earlier, more proactive and robust clinical supply chain planning, and reduce the risk of delays and budget overspend common to clinical trials as they progress.

Smarter clinical trial supply planning

The CTSuccess service uses Catalent’s proprietary StartScore evaluation tool to calculate the complexity of a potential clinical project across more than a dozen specific and objective study characteristics. The StartScore model was developed by the company’s in-house supply chain experts based on actual performance data. The risk-based score generated by the tool helps sponsors gain advance understanding of the appropriate level of clinical supply management oversight needed to help get their project started on time and maintain momentum as the study progresses.

“No two studies are the same, and each carries its own unique risks and presents individual challenges, but the aim of CTSuccess is to use the experience we have as a company in supplying materials for thousands of trials to identify the characteristics of a project upfront and highlight potential risk factors that may arise,” commented Kristen Devito, Global Director, Catalent Clinical Supply Services. “Once these risks have been identified then a project team can be put together combining the necessary expertise to provide the integrated services and tailored support to ensure continuity of supply from beginning to end.”

Read More

Related news

FDA success for MedPharm Centre of Excellence

FDA success for MedPharm Centre of Excellence

14 Feb 2020

The inspection was triggered by data generated by MedPharm as part of a client’s ANDA for a generic topical product.

Read more 
Stevanato Group partners with Pfeiffer Vacuum to deliver effective biopharma industry testing

Stevanato Group partners with Pfeiffer Vacuum to deliver effective biopharma industry testing

12 Feb 2020

Partnership will provide biopharma companies with advanced container closure integrity analysis and testing protocols.

Read more 
Catalent to manufacture first-in-class mAb targeting solid tumours

Catalent to manufacture first-in-class mAb targeting solid tumours

11 Feb 2020

ZM008 could have potential benefits for the treatment of prostate cancer.

Read more 
BD completes clinical trial for its wearable injector

BD completes clinical trial for its wearable injector

11 Feb 2020

The pre-filled, pre-assembled injector is designed to prioritize safety, convenience and usability while delivering high-value drug treatments in the comfort of an in-home environment.

Read more 
Innovation awarded at Pharmapack

Innovation awarded at Pharmapack

10 Feb 2020

Innovations across primary and secondary packaging, drug delivery devices, and machinery acknowledged in Exhibitor Innovations, with Health Product Awards for patient-centricity and eco-design.

Read more 
2020 - a year for 'big answers' rather than 'big data'

2020 - a year for 'big answers' rather than 'big data'

7 Feb 2020

Zenith Technologies CEO, Joe Haugh, takes us through how the business has evolved this year, to better meet the needs of its customers, as well as the trends they see shaping the industry through 2020 and beyond.

Read more 
Recipharm acquisition to make it a top 5 global CDMO?

Recipharm acquisition to make it a top 5 global CDMO?

6 Feb 2020

CEO says the acquisition of Consort Medical will help to create a leading advanced delivery systems company.

Read more 
New Velesco Pharma clinical manufacturing facility begins operations

New Velesco Pharma clinical manufacturing facility begins operations

5 Feb 2020

The facility will triple the company’s cGMP clinical trial manufacturing capacity.

Read more 
Colorcon starts No-Tox ink manufacturing at new UK facility

Colorcon starts No-Tox ink manufacturing at new UK facility

4 Feb 2020

The additional capacity will provide customers with shorter lead times and reduced transportation costs.

Read more 
Hovione announces key patent grants for its large dose DPI

Hovione announces key patent grants for its large dose DPI

4 Feb 2020

TwinMax enabes delivery of doses up to 100 mg formulated as drug alone or engineered particles.

Read more